<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03990636</url>
  </required_header>
  <id_info>
    <org_study_id>INCABrazilCOPQ</org_study_id>
    <nct_id>NCT03990636</nct_id>
  </id_info>
  <brief_title>Photodynamic Therapy With Metil 5-aminolevulinate for Actinic Cheilitis - Phase 2 Clinical Trial</brief_title>
  <acronym>PDTMALAC</acronym>
  <official_title>Photodynamic Therapy With Metil 5-aminolevulinate for Actinic Cheilitis - A Phase 2 Randomized Double-blind Placebo Controlled Clinical Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Instituto Nacional de Cancer, Brazil</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Instituto Nacional de Cancer, Brazil</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      Brazil is a tropical country, with high incidence of ultraviolet radiation throughout the
      year. Many Europeans migrated to Brazil escaping either war or economic crisis to live in the
      country searching for opportunities. Low phototype combined with high incidence of UV light
      is a combination that not only affect the skin but also the lips. The current study was
      designed to use photodynamic therapy with metil 5-aminolevulinate for actinic cheilitis in a
      phase 2 clinical trial.
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">October 17, 2019</start_date>
  <completion_date type="Anticipated">December 15, 2021</completion_date>
  <primary_completion_date type="Anticipated">May 15, 2020</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Complete clinical response</measure>
    <time_frame>18 months</time_frame>
    <description>Expected complete clinical response in 60% of cases</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Histological cure</measure>
    <time_frame>18 months</time_frame>
    <description>Expected histological cure in 40% of cases</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>IHC analysis</measure>
    <time_frame>18 months</time_frame>
    <description>Expression of immunohistochemical markers of cancer progression</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">40</enrollment>
  <condition>Actinic Cheilitis</condition>
  <condition>Leukoplakia</condition>
  <condition>Erythroplakia</condition>
  <arm_group>
    <arm_group_label>Metil 5-aminolevulinate arm</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Metil 5-aminolevulinate arm with photo activation.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo arm</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo (without metil 5-aminolevulinate) arm with photo activation.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Metil 5-aminolevulinate</intervention_name>
    <description>Scrubbing lip vermillion and applying the medication or placebo that is activated (or not, in case of placebo) with red light.</description>
    <arm_group_label>Metil 5-aminolevulinate arm</arm_group_label>
    <arm_group_label>Placebo arm</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Clinical diagnosis with histopathological confirmation of actinic cheilitis

          -  Patients will be requested to respect the timeframe of clinical consultations

          -  No treatment for actinic cheilitis in the last 3 months

        Exclusion Criteria:

          -  Histopathological diagnosis of squamous cell carcinoma (SCC)

          -  Patient presenting any type of immunosupression

          -  Recurrent crust of the lip vermilion (high risk of SCC)
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Daniel Cohen Goldemberg, PhD</last_name>
    <phone>+5521988167978</phone>
    <email>daniel.cohen@inca.gov.br</email>
  </overall_contact>
  <verification_date>June 2019</verification_date>
  <study_first_submitted>June 17, 2019</study_first_submitted>
  <study_first_submitted_qc>June 17, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">June 19, 2019</study_first_posted>
  <last_update_submitted>June 17, 2019</last_update_submitted>
  <last_update_submitted_qc>June 17, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">June 19, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Instituto Nacional de Cancer, Brazil</investigator_affiliation>
    <investigator_full_name>Daniel Cohen Goldenberg</investigator_full_name>
    <investigator_title>Photodynamic therapy with methyl aminolevulinate in the treatment of actinic cheilitis</investigator_title>
  </responsible_party>
  <keyword>PDT</keyword>
  <keyword>Actinic Cheilitis</keyword>
  <keyword>Phase 2 Clinical Trial</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Leukoplakia</mesh_term>
    <mesh_term>Cheilitis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Aminolevulinic Acid</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
    <ipd_description>The Informed Consent Form (ICF) will be read and explained to each patient informing about all the risks and potential benefits. Clinical Study Report (CSR) is going to be registered for all patients, although data will not be shared.</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

